Dyne Therapeutics Inc Ordinary Shares DYN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DYN is a good fit for your portfolio.
News
-
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
-
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
-
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
-
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
-
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
-
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
-
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
-
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
Trading Information
- Previous Close Price
- $42.70
- Day Range
- $42.84–44.88
- 52-Week Range
- $6.40–45.46
- Bid/Ask
- $39.87 / $46.00
- Market Cap
- $4.43 Bil
- Volume/Avg
- 955,487 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 143
- Website
- https://www.dyne-tx.com
Comparables
Valuation
|
Metric
|
DYN
|
EWTX
|
GBIO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 8.11 | 3.31 | 1.77 |
Price/Sales | — | — | 23.26 |
Price/Cash Flow | — | — | — |
Price/Earnings
DYN
EWTX
GBIO
Financial Strength
|
Metric
|
DYN
|
EWTX
|
GBIO
|
|---|---|---|---|
Quick Ratio | 20.28 | 36.49 | 7.75 |
Current Ratio | 21.83 | 37.08 | 8.01 |
Interest Coverage | — | — | — |
Quick Ratio
DYN
EWTX
GBIO
Profitability
|
Metric
|
DYN
|
EWTX
|
GBIO
|
|---|---|---|---|
Return on Assets (Normalized) | −77.53% | −23.18% | −23.97% |
Return on Equity (Normalized) | −94.92% | −24.45% | −40.92% |
Return on Invested Capital (Normalized) | −88.19% | −28.92% | −33.29% |
Return on Assets
DYN
EWTX
GBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Bfpgmnykw | Jcjj | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mpdbrqd | Jgqnh | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fqxbmgk | Rcqhbq | $118.7 Bil | |||
| Moderna Inc
MRNA
| Bdrbjjg | Nkr | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yzlsffr | Qqjkb | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Mvsgzxff | Dcfmd | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Grhszcwr | Jcw | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Phyywrnr | Shdmwvw | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Jqtqmskq | Bmjrk | $15.0 Bil | |||
| Incyte Corp
INCY
| Gcrdvfg | Rcghg | $13.5 Bil |